Now livetag icon
Ad Intelligence Presents: Ads in ChatGPT & Google. Download the reportbanner icon
Mediderma

April 2026

Mediderma Market Share Analysis for April 2026

Exoses LB+ es una solución estéril a base de exosomas de origen bacterial que junto a los activos vitalizantes, devuelve la piel a los orígenes de la juventud.
Industry: N/A
Year Founded1989
Employees51 - 200
Annual Revenue$15M - $25M
mediderma.com
Mediderma
Mediderma (including company regionals)
  • mediderma.com
    mediderma.com
See more website traffic and engagement information

Mediderma Revenue up to April 2026 is 15M - 25M

revenue generated by Mediderma top domains

Mediderma top domains revenue over 3 years

Revenue for Mediderma top domains

mediderma.commediderma.com15M - 25M
See more with Sales Intelligence

Total visits to Mediderma's top domains

Understand Mediderma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in Mediderma's top domains

Analyze Mediderma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on Mediderma's top domains

See how Mediderma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.



Top technologies used by Mediderma

These are the website technologies, by industry, used by Mediderma top domains

Social (11)

Google+ Platform

Google+ Platform

Advertising (6)

Google Adsense

Google Adsense

Payment & Currencies (4)

Cart Functionality

Cart Functionality

Audio Video Media (2)

YouTube

YouTube

More Technologies

13

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.